Drug safety updates, recalls and regulatory warnings from MHRA, organised for rapid clinical review and specialty follow-up.
#MedSafetyWeek 2026: Key Takeaways for Clinicians Encourage patient reporting: MedSafetyWeek (2-8 November 2026) emphasises the critical importance of reporting suspected adverse drug reactions and medical device incidents via the Yellow Card scheme to improve…
26 Oct 2026 · Read clinical summaryThe Commission on Human Medicines (CHM) has temporarily restricted use of the IXCHIQ Chikungunya vaccine in people aged 65 years and over following very rare fatal reactions reported…
IXCHIQ Chikungunya vaccine: updates to restrictions of use following safety revi...
Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ische...
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warni...
The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023.…
The MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in the Public Assessment Report) were that…
Rybelsus ® (semaglutide tablets): transition to new formulation and risk of med...
Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for IIH are being added to the product information…
The Commission on Human Medicines (CHM) has endorsed changes to isotretinoin prescribing guidance. In addition, CHM is seeking further information from dermatology services who prescribe isotretinoin to inform…
The annual #MedSafetyWeek campaign takes place from 3 to 9 November 2025. This year’s campaign theme is ‘we can all help make medicines safer.’ This update is best…
Patients should be reminded and reassured that there is no evidence that taking paracetamol during pregnancy causes autism in children. Paracetamol is recommended as the first-choice pain reliever…
There is a small increase in the risk of Guillain-Barré syndrome following vaccination with Abrysvo (Pfizer respiratory syncytial virus (RSV) vaccine) and Arexvy (GSK RSV vaccine) in adults…